US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MBX Biosciences

34.74

-0.9000-2.53%

Volume:134.15K

Turnover:4.68M

Market Cap:1.56B

PE:-14.53

High:35.70

Open:35.57

Low:34.28

Close:35.64

52wk High:44.89

52wk Low:4.81

Shares:44.90M

Float Shares:25.72M

Volume Ratio:0.50

T/O Rate:0.52%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.3917

EPS(LYR):-5.8181

ROE:-24.43%

ROA:-16.64%

PB:4.03

PE(LYR):-5.97

Loading ...

Overview Company News Filings

Mbx Biosciences Inc - Two New Obesity Candidates to Be Nominated in 2026

THOMSON REUTERS

MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference

Is UBS’s Canvuparatide Focus Altering The Investment Case For MBX Biosciences (MBX)?

Simply Wall St.

Microbix Tightens EBITDA Disclosure After OSC Review

MBX Biosciences Initiated at Buy by UBS

UBS Initiates MBX Biosciences at Buy With $60 Price Target

MT Newswires Live

What MBX Biosciences (MBX)'s Goldman Sell Rating and Pipeline Progress Means For Shareholders

Simply Wall St.

A Look at MBX Biosciences (MBX) Valuation After Goldman Sachs’ Bearish Initiation of Coverage

Simply Wall St.

MBX Biosciences to Present at J.P. Morgan Healthcare Conference

Goldman Sachs Initiates Coverage on MBX Biosciences With Sell Rating, $18 Price Target

MT Newswires Live

Why MBX Biosciences (MBX) Is Up 9.2% After Positive Phase 2 Data and $199.9M Fundraise

Simply Wall St.

MBX Biosciences to Present at Piper Sandler Healthcare Conference

MBX Biosciences, Inc.: Strong Financial Outlook and Strategic Direction Support Buy Rating

MBX Biosciences Reports Q3 2025 Financial Results

MBX Biosciences Is Maintained at Buy by Guggenheim

Biotech stocks are coming back. Here's what's driving the sector higher.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zymeworks (ZYME), MBX Biosciences, Inc. (MBX) and Lemaitre Vascular (LMAT)

MBX Biosciences, Inc. (MBX) Receives a Buy from Mizuho Securities

BRIEF-Mbx Biosciences To Offer Up To $400 Million In Securities - SEC Filing

Mbx Biosciences Inc - to Offer up to $400 Mln in Securities - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MBX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MBX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","market":"US","secType":"STK","nameCN":"MBX Biosciences","latestPrice":34.74,"timestamp":1772127469568,"preClose":35.64,"halted":0,"volume":134146,"delay":0,"changeRate":-0.025252525252525214,"floatShares":25718200,"shares":44902302,"eps":-2.391686,"marketStatus":"Trading","change":-0.9,"latestTime":"02-26 12:37:49 EST","open":35.57,"high":35.7,"low":34.28,"amount":4675028.3438,"amplitude":0.039843,"askPrice":34.92,"askSize":28,"bidPrice":34.73,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.391686,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772139600000},"marketStatusCode":2,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":35.64,"preHourTrading":{"tag":"盘前","latestPrice":35.67,"preClose":35.64,"latestTime":"09:29 EST","volume":8339,"amount":297413.620498,"timestamp":1772116171072,"change":0.03,"changeRate":0.000842,"amplitude":0.047699},"postHourTrading":{"tag":"盘后","latestPrice":36.4,"preClose":35.64,"latestTime":"18:22 EST","volume":7289,"amount":261625.055,"timestamp":1772061751350,"change":0.76,"changeRate":0.021324,"amplitude":0.021324},"volumeRatio":0.504904,"impliedVol":0.9139,"impliedVolPercentile":0.2477},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","floatShares":25718200,"roa":"-16.64%","roe":"-24.43%","lyrEps":-5.818121,"volumeRatio":0.504904,"shares":44902302,"dividePrice":0,"high":35.7,"amplitude":0.039843,"preClose":35.64,"low":34.28,"week52Low":4.8069,"pbRate":"4.03","week52High":44.89,"institutionHeld":0,"latestPrice":34.74,"committee":0.754386,"eps":-2.391686,"divideRate":0,"volume":134146,"delay":0,"ttmEps":-2.391686,"open":35.57,"prevYearClose":31.54,"prevWeekClose":34.79,"prevMonthClose":36.85,"prevQuarterClose":31.54,"fiveDayClose":37.26,"twentyDayClose":35.83,"sixtyDayClose":34.49},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MBX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"MBX","fiscalQuarterEnding":"2025/09","expectedEps":-0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.63},{"market":"US","date":"2025-08-07","symbol":"MBX","fiscalQuarterEnding":"2025/06","expectedEps":-0.77,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.58},{"market":"US","date":"2025-05-12","symbol":"MBX","fiscalQuarterEnding":"2025/03","expectedEps":-0.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.71},{"market":"US","date":"2025-03-17","symbol":"MBX","fiscalQuarterEnding":"2024/12","expectedEps":-0.59,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"pre","actualEps":-0.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MBX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MBX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3636,"buy":0.5455,"hold":0,"sell":0.0909,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5455,"analysts":11,"updateTime":1769922000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MBX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MBX","date":"2026-02-25","current":-14.901622,"percent":0.046703,"low":-24.064666,"twenty":-16.351818,"median":-8.580935,"eighty":-5.433251,"high":-3.125337,"avg":-10.454464,"sd":5.632565,"marketCap":1731940268},"quantilePoints":[{"date":"2024-09-13","current":-15.960592,"twenty":-13.895501,"median":-10.797864,"eighty":-10.797864,"marketCap":753339957},{"date":"2024-09-20","current":-15.949203,"twenty":-15.694582,"median":-15.111074,"eighty":-12.419885,"marketCap":752802389},{"date":"2024-09-27","current":-16.939398,"twenty":-16.33255,"median":-15.751164,"eighty":-14.917986,"marketCap":799539567},{"date":"2024-10-04","current":-16.797941,"twenty":-16.986079,"median":-16.110499,"eighty":-15.091977,"marketCap":792862827},{"date":"2024-10-11","current":-16.932325,"twenty":-16.986079,"median":-16.31699,"eighty":-15.248994,"marketCap":799205730},{"date":"2024-10-18","current":-17.024271,"twenty":-17.032759,"median":-16.518565,"eighty":-15.369232,"marketCap":803545610},{"date":"2024-10-25","current":-15.022664,"twenty":-17.021442,"median":-16.380645,"eighty":-15.369232,"marketCap":709069745},{"date":"2024-11-01","current":-15.885548,"twenty":-16.991737,"median":-16.362963,"eighty":-15.369232,"marketCap":749797857},{"date":"2024-11-08","current":-13.874718,"twenty":-16.947885,"median":-16.309917,"eighty":-15.248994,"marketCap":765593046},{"date":"2024-11-15","current":-10.66494,"twenty":-16.936569,"median":-16.143706,"eighty":-14.480386,"marketCap":588480730},{"date":"2024-11-22","current":-11.203941,"twenty":-16.918179,"median":-15.949203,"eighty":-13.805677,"marketCap":618222233},{"date":"2024-11-29","current":-12.318278,"twenty":-16.877157,"median":-15.751164,"eighty":-12.380051,"marketCap":679710282},{"date":"2024-12-06","current":-13.432616,"twenty":-16.771064,"median":-15.461179,"eighty":-11.837418,"marketCap":741198331},{"date":"2024-12-13","current":-11.470413,"twenty":-16.663558,"median":-15.31265,"eighty":-11.837418,"marketCap":632925896},{"date":"2024-12-20","current":-12.330391,"twenty":-16.662143,"median":-15.019127,"eighty":-11.803503,"marketCap":680378630},{"date":"2024-12-27","current":-12.154761,"twenty":-16.656485,"median":-14.542475,"eighty":-11.803503,"marketCap":670687579},{"date":"2025-01-03","current":-11.258446,"twenty":-16.435813,"median":-14.054537,"eighty":-11.676323,"marketCap":621229800},{"date":"2025-01-10","current":-8.290916,"twenty":-16.380645,"median":-13.850493,"eighty":-11.492215,"marketCap":457484452},{"date":"2025-01-17","current":-5.989566,"twenty":-16.372157,"median":-13.75965,"eighty":-11.117943,"marketCap":330498264},{"date":"2025-01-24","current":-6.510398,"twenty":-16.36367,"median":-13.256987,"eighty":-10.797864,"marketCap":359237243},{"date":"2025-01-31","current":-6.06224,"twenty":-16.342452,"median":-12.878476,"eighty":-9.893382,"marketCap":334508354},{"date":"2025-02-07","current":-7.473331,"twenty":-16.314161,"median":-12.457571,"eighty":-8.809325,"marketCap":412370938},{"date":"2025-02-14","current":-6.304488,"twenty":-16.290113,"median":-12.324334,"eighty":-7.444262,"marketCap":347875321},{"date":"2025-02-21","current":-6.589128,"twenty":-16.247676,"median":-12.215323,"eighty":-7.171733,"marketCap":363581507},{"date":"2025-02-28","current":-5.813937,"twenty":-16.175534,"median":-12.009413,"eighty":-6.798672,"marketCap":320807212},{"date":"2025-03-07","current":-5.989566,"twenty":-16.064646,"median":-11.803503,"eighty":-6.591551,"marketCap":330498264},{"date":"2025-03-14","current":-5.26888,"twenty":-15.958314,"median":-11.682379,"eighty":-6.514032,"marketCap":290731536},{"date":"2025-03-21","current":-4.258879,"twenty":-15.936472,"median":-11.549143,"eighty":-6.294798,"marketCap":263718287},{"date":"2025-03-28","current":-4.188707,"twenty":-15.858671,"median":-11.258446,"eighty":-6.213645,"marketCap":259373118},{"date":"2025-04-04","current":-3.260282,"twenty":-15.749749,"median":-11.107042,"eighty":-6.057395,"marketCap":201883200},{"date":"2025-04-11","current":-3.999783,"twenty":-15.687509,"median":-10.797864,"eighty":-5.922948,"marketCap":247674589},{"date":"2025-04-17","current":-4.113138,"twenty":-15.461179,"median":-10.66494,"eighty":-5.686757,"marketCap":254693707},{"date":"2025-04-25","current":-4.949799,"twenty":-15.461179,"median":-9.901861,"eighty":-5.438453,"marketCap":306501482},{"date":"2025-05-02","current":-6.477382,"twenty":-15.454106,"median":-9.653557,"eighty":-5.327647,"marketCap":401092452},{"date":"2025-05-09","current":-5.996976,"twenty":-15.31265,"median":-8.539219,"eighty":-5.438453,"marketCap":371344761},{"date":"2025-05-16","current":-5.077465,"twenty":-15.206557,"median":-7.473331,"eighty":-5.077465,"marketCap":373015980},{"date":"2025-05-23","current":-5.691675,"twenty":-15.022664,"median":-7.246225,"eighty":-5.226487,"marketCap":418138881},{"date":"2025-05-30","current":-5.787218,"twenty":-15.017006,"median":-7.134185,"eighty":-5.260401,"marketCap":425157999},{"date":"2025-06-06","current":-5.395944,"twenty":-14.885451,"median":-6.813207,"eighty":-5.315894,"marketCap":396413040},{"date":"2025-06-13","current":-4.877278,"twenty":-14.35621,"median":-6.707223,"eighty":-5.172099,"marketCap":358309257},{"date":"2025-06-20","current":-4.677092,"twenty":-14.130289,"median":-6.595185,"eighty":-5.059804,"marketCap":343602533},{"date":"2025-06-27","current":-5.136611,"twenty":-14.052953,"median":-6.564904,"eighty":-5.017962,"marketCap":377361148},{"date":"2025-07-03","current":-5.673476,"twenty":-13.977856,"median":-6.515167,"eighty":-5.013234,"marketCap":416801906},{"date":"2025-07-11","current":-5.641628,"twenty":-13.855338,"median":-6.4303,"eighty":-5.035235,"marketCap":414462200},{"date":"2025-07-18","current":-5.548359,"twenty":-13.804466,"median":-6.320845,"eighty":-5.055522,"marketCap":407610204},{"date":"2025-07-25","current":-5.928259,"twenty":-13.766918,"median":-6.298431,"eighty":-5.072006,"marketCap":435519554},{"date":"2025-08-01","current":-6.028352,"twenty":-13.628836,"median":-6.310434,"eighty":-5.101123,"marketCap":442872915},{"date":"2025-08-08","current":-4.830149,"twenty":-13.362364,"median":-6.283291,"eighty":-5.101123,"marketCap":372013249},{"date":"2025-08-15","current":-5.76189,"twenty":-13.198847,"median":-6.22399,"eighty":-5.101123,"marketCap":443774969},{"date":"2025-08-22","current":-6.171895,"twenty":-13.089836,"median":-6.221845,"eighty":-5.14935,"marketCap":475353203},{"date":"2025-08-29","current":-6.224236,"twenty":-12.914207,"median":-6.224236,"eighty":-5.170279,"marketCap":479384467},{"date":"2025-09-05","current":-5.635398,"twenty":-12.685283,"median":-6.241684,"eighty":-5.176649,"marketCap":434032748},{"date":"2025-09-12","current":-4.331231,"twenty":-12.593229,"median":-6.221845,"eighty":-5.070186,"marketCap":333587089},{"date":"2025-09-19","current":-4.392296,"twenty":-12.449092,"median":-6.213645,"eighty":-5.008506,"marketCap":338290230},{"date":"2025-09-26","current":-10.057984,"twenty":-12.39822,"median":-6.217295,"eighty":-5.008506,"marketCap":774655869},{"date":"2025-10-03","current":-9.721364,"twenty":-12.327968,"median":-6.224236,"eighty":-5.029502,"marketCap":748729706},{"date":"2025-10-10","current":-9.207959,"twenty":-12.309799,"median":-6.253122,"eighty":-5.039662,"marketCap":709187798},{"date":"2025-10-17","current":-7.994552,"twenty":-12.25166,"median":-6.280939,"eighty":-5.051241,"marketCap":615732407},{"date":"2025-10-24","current":-9.364715,"twenty":-12.13417,"median":-6.307461,"eighty":-5.070186,"marketCap":721260982},{"date":"2025-10-31","current":-12.650784,"twenty":-12.13417,"median":-6.352937,"eighty":-5.089294,"marketCap":974350701},{"date":"2025-11-07","current":-13.743232,"twenty":-12.309799,"median":-6.369154,"eighty":-5.142981,"marketCap":1106261420},{"date":"2025-11-14","current":-13.426901,"twenty":-12.512852,"median":-6.477382,"eighty":-5.169369,"marketCap":1080798409},{"date":"2025-11-21","current":-15.07807,"twenty":-12.739549,"median":-6.521866,"eighty":-5.176649,"marketCap":1213709223},{"date":"2025-11-28","current":-19.239461,"twenty":-13.256987,"median":-6.567932,"eighty":-5.191208,"marketCap":1548680395},{"date":"2025-12-05","current":-17.036043,"twenty":-13.72255,"median":-6.589128,"eighty":-5.211681,"marketCap":1371316303},{"date":"2025-12-12","current":-15.859028,"twenty":-13.826268,"median":-6.619611,"eighty":-5.226487,"marketCap":1276572445},{"date":"2025-12-19","current":-15.992906,"twenty":-14.046615,"median":-6.70403,"eighty":-5.26888,"marketCap":1287348998},{"date":"2025-12-26","current":-17.911832,"twenty":-14.268105,"median":-6.806351,"eighty":-5.279538,"marketCap":1441812917},{"date":"2026-01-02","current":-17.59387,"twenty":-14.917986,"median":-6.813207,"eighty":-5.295223,"marketCap":1416218605},{"date":"2026-01-09","current":-17.136452,"twenty":-15.146199,"median":-7.076651,"eighty":-5.307262,"marketCap":1379398717},{"date":"2026-01-16","current":-22.820712,"twenty":-15.452731,"median":-7.200803,"eighty":-5.317689,"marketCap":1836953174},{"date":"2026-01-23","current":-23.646296,"twenty":-15.472295,"median":-7.424882,"eighty":-5.324948,"marketCap":1903408581},{"date":"2026-01-30","current":-20.550355,"twenty":-15.847871,"median":-7.61062,"eighty":-5.334947,"marketCap":1654200805},{"date":"2026-02-06","current":-20.109671,"twenty":-15.97998,"median":-7.994552,"eighty":-5.365916,"marketCap":1618727987},{"date":"2026-02-13","current":-22.260078,"twenty":-16.085028,"median":-8.265761,"eighty":-5.405044,"marketCap":1791824944},{"date":"2026-02-20","current":-21.826592,"twenty":-16.300015,"median":-8.354645,"eighty":-5.422333,"marketCap":1756931510},{"date":"2026-02-25","current":-21.516122,"twenty":-16.351818,"median":-8.580935,"eighty":-5.433251,"marketCap":1731940268}],"updateTime":1772113457523},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MBX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2602343568","title":"Mbx Biosciences Inc - Two New Obesity Candidates to Be Nominated in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602343568","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602343568?lang=en_us&edition=fundamental","pubTime":"2026-01-12 05:00","pubTimestamp":1768165202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUATNCVP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2602686805","title":"MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602686805","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602686805?lang=en_us&edition=fundamental","pubTime":"2026-01-12 05:00","pubTimestamp":1768165200,"startTime":"0","endTime":"0","summary":"One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-we","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/11/3216493/0/en/MBX-Biosciences-to-Provide-2026-Outlook-and-Business-Update-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772923.USD","LU0158827948.USD","LU0314104364.USD","LU2023251221.USD","PBH","LU0225283273.USD","XBI","LU2028103732.USD","HCSG","BK4588","LU0234570918.USD","LU0557290698.USD","LU1668664300.SGD","BK4137","MBX","BK4581","BK4516","LU0795875086.SGD","LU1548497426.USD","LU0106831901.USD","LU2133065610.SGD","LU0106261372.USD","LU1791710582.SGD","LU0029874061.USD","LU0795875169.SGD","LU0882574139.USD","LU2111349929.HKD","LU1162221912.USD","LU0528227936.USD","LU2089284900.SGD","BK4585","XLV","LABU","IE00BKVL7J92.USD","LU1244550221.USD","LU0128526141.USD","LU0158827781.USD","LU0098860793.USD","IE00BZ1G4Q59.USD","LU0267386448.USD","LU0320765646.SGD","LU1074936037.SGD","LU2271345857.HKD","LU1244550577.SGD","LU1791710400.SGD","LU1720051108.HKD","BK4504","LU1363072403.SGD","LU2347655156.SGD","HP"],"gpt_icon":0},{"id":"2602830617","title":"Is UBS’s Canvuparatide Focus Altering The Investment Case For MBX Biosciences (MBX)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2602830617","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602830617?lang=en_us&edition=fundamental","pubTime":"2026-01-10 02:43","pubTimestamp":1767984186,"startTime":"0","endTime":"0","summary":"UBS recently initiated coverage on MBX Biosciences with a Buy rating, highlighting the company’s pipeline of long-acting therapies for metabolic and endocrine diseases, including once-weekly canvuparatide and a monthly GLP-1 obesity program.\nThe focus on upcoming clinical milestones for these programs, underpinned by MBX Biosciences’ strong liquidity and zero debt, has sharpened investor attention on its R&D-driven business model.\nWe’ll now examine how UBS’s emphasis on MBX Biosciences’...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/is-ubss-canvuparatide-focus-altering-the-investment-case-for","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/is-ubss-canvuparatide-focus-altering-the-investment-case-for","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2602376497","title":"Microbix Tightens EBITDA Disclosure After OSC Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2602376497","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602376497?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:15","pubTimestamp":1767964558,"startTime":"0","endTime":"0","summary":"Microbix Biosystms ( ($TSE:MBX) ) has issued an update. Microbix Biosystems Inc., a Canadian life sciences manufacturer specializing in antigens, q...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-tightens-ebitda-disclosure-after-osc-review?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-tightens-ebitda-disclosure-after-osc-review?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2601386691","title":"MBX Biosciences Initiated at Buy by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2601386691","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601386691?lang=en_us&edition=fundamental","pubTime":"2026-01-08 04:33","pubTimestamp":1767817980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MBX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 07, 2026 15:33 ET (20:33 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2601804852","title":"UBS Initiates MBX Biosciences at Buy With $60 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2601804852","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601804852?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:53","pubTimestamp":1767797603,"startTime":"0","endTime":"0","summary":"MBX Biosciences (MBX) has an average rating of buy and mean price target of $59.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MBX"],"gpt_icon":0},{"id":"2592173491","title":"What MBX Biosciences (MBX)'s Goldman Sell Rating and Pipeline Progress Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2592173491","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592173491?lang=en_us&edition=fundamental","pubTime":"2025-12-20 14:19","pubTimestamp":1766211599,"startTime":"0","endTime":"0","summary":"Goldman Sachs recently initiated coverage of MBX Biosciences with a Sell rating, citing concerns about the company’s ability to validate its platform beyond lead candidate canvuparatide and the potential differentiation of upcoming post-bariatric hypoglycemia data expected in 2026.\nAt the same time, MBX Biosciences is moving its endocrine and metabolic pipeline toward later-stage development, including Phase 3 planning for canvuparatide and increased visibility through events such as the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/what-mbx-biosciences-mbxs-goldman-sell-rating-and-pipeline-p","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/what-mbx-biosciences-mbxs-goldman-sell-rating-and-pipeline-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PRGS","MBX"],"gpt_icon":0},{"id":"2592131153","title":"A Look at MBX Biosciences (MBX) Valuation After Goldman Sachs’ Bearish Initiation of Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=2592131153","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592131153?lang=en_us&edition=fundamental","pubTime":"2025-12-19 13:22","pubTimestamp":1766121723,"startTime":"0","endTime":"0","summary":"MBX Biosciences (MBX) slipped onto more traders radars after Goldman Sachs launched coverage with a bearish stance, questioning how much value the company can prove beyond its lead hormone therapy canvuparatide.\nSee our latest analysis for MBX Biosciences.\nDespite Goldman’s cautious view, MBX’s recent 1 day share price return of 3.5 percent to 28.67 dollars comes after a powerful 90 day share price return of 186.7 percent and 1 year total shareholder return of 40.8 percent, suggesting...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/a-look-at-mbx-biosciences-mbx-valuation-after-goldman-sachs","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/a-look-at-mbx-biosciences-mbx-valuation-after-goldman-sachs","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1868837300.USD","IE00B19Z3581.USD","LU2237443895.HKD","LU2471134796.USD","LU2750360997.AUD","BK4552","BK4504","BK4533","LU0048573561.USD","LU1868837136.USD","LU1894683264.USD","LU0106831901.USD","BK4007","LU2750360641.GBP","LU0096364046.USD","LU2237443382.USD","IE0004091025.USD","LU1868836591.USD","LU0251142724.SGD","LU2265009873.SGD","LU2471134952.CNY","IE00BSNM7G36.USD","BK4588","IE0002270589.USD","LU1804176565.USD","IE0004086264.USD","LU2237438978.USD","BK4550","LU0742534661.SGD","IE00BFXG1179.USD","LU0345770308.USD","LU2471134879.HKD","BK4516","LU2237443465.HKD","MBX","LU0345770993.USD","LU0061475181.USD","BK4585","LU1894683348.USD","LU1791807156.HKD","LU2237443622.USD","LU2471134523.USD","LU2237443978.SGD","IE00B19Z3B42.SGD","LU0251131958.USD","LU1868836757.USD","BK4127","IE0034235188.USD","LU1868836914.USD","LU2237443549.SGD"],"gpt_icon":0},{"id":"2591649610","title":"MBX Biosciences to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649610","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649610?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803611,"startTime":"0","endTime":"0","summary":"MBX Biosciences Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, in San Francisco, California. The company's President and CEO, Kent Hawryluk, is scheduled to give a company presentation and participate in one-on-one meetings. The event will be accessible via a live webcast on the MBX Biosciences website, with a replay available for approximately 90 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on December 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLvMmrJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210150020.SGD","MBX","SG9999014005.SGD","SG9999014013.SGD","SG9999014039.USD","BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","SG9999014021.USD","BK4585","IE00BGHQF748.EUR","BK4588","IE00B64PRP62.GBP","LU0314104364.USD","LU2210149790.SGD","BK4007"],"gpt_icon":0},{"id":"2588513881","title":"Goldman Sachs Initiates Coverage on MBX Biosciences With Sell Rating, $18 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2588513881","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588513881?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:28","pubTimestamp":1764851288,"startTime":"0","endTime":"0","summary":"MBX Biosciences (MBX) has an average rating of Buy and mean price target of $64.43, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MBX"],"gpt_icon":0},{"id":"2585100368","title":"Why MBX Biosciences (MBX) Is Up 9.2% After Positive Phase 2 Data and $199.9M Fundraise","url":"https://stock-news.laohu8.com/highlight/detail?id=2585100368","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585100368?lang=en_us&edition=fundamental","pubTime":"2025-11-23 12:29","pubTimestamp":1763872161,"startTime":"0","endTime":"0","summary":"Jefferies reiterated a Buy rating on MBX Biosciences after the company reported strong Phase 2 data for its lead hypoparathyroidism therapy, canvuparatide, and announced an upsized public offering expected to raise approximately US$199.9 million to advance its pipeline.\nThis influx of capital positions MBX Biosciences to pursue Phase 3 trials and regulatory interactions with both the FDA and EMA for its novel treatment.\nWe'll examine how the successful fundraise and pipeline progress...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/why-mbx-biosciences-mbx-is-up-92-after-positive-phase-2-data","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/why-mbx-biosciences-mbx-is-up-92-after-positive-phase-2-data","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2584937719","title":"MBX Biosciences to Present at Piper Sandler Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2584937719","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584937719?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:03","pubTimestamp":1763471010,"startTime":"0","endTime":"0","summary":"MBX Biosciences Inc. will participate in the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025, in New York, NY. President and CEO Kent Hawryluk and Chief Medical Officer Sam Azoulay will present and take part in a fireside chat and one-on-one meetings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on November 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL1LP0Kk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU2210149790.SGD","NDAQ","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","MBX","BK4007","IE00B64PRP62.GBP","BK4588"],"gpt_icon":0},{"id":"2583590198","title":"MBX Biosciences, Inc.: Strong Financial Outlook and Strategic Direction Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2583590198","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583590198?lang=en_us&edition=fundamental","pubTime":"2025-11-14 01:05","pubTimestamp":1763053542,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on MBX stock, giving a Buy rating on November 7. Tyler Van Buren’s rating is b...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/mbx-biosciences-inc-strong-financial-outlook-and-strategic-direction-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/mbx-biosciences-inc-strong-financial-outlook-and-strategic-direction-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX"],"gpt_icon":0},{"id":"2583323955","title":"MBX Biosciences Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583323955","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583323955?lang=en_us&edition=fundamental","pubTime":"2025-11-13 12:42","pubTimestamp":1763008956,"startTime":"0","endTime":"0","summary":"MBX Biosciences, Inc. ( ($MBX) ) has released its Q3 earnings. Here is a breakdown of the information MBX Biosciences, Inc. presented to its invest...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2582187020","title":"MBX Biosciences Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2582187020","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582187020?lang=en_us&edition=fundamental","pubTime":"2025-11-10 23:07","pubTimestamp":1762787220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MBX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 10:07 ET (15:07 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX"],"gpt_icon":0},{"id":"2582865291","title":"Biotech stocks are coming back. Here's what's driving the sector higher.","url":"https://stock-news.laohu8.com/highlight/detail?id=2582865291","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582865291?lang=en_us&edition=fundamental","pubTime":"2025-11-09 00:57","pubTimestamp":1762621020,"startTime":"0","endTime":"0","summary":"The volatile sector is seeing greater stability, and these four stocks can profit. Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 percentage points.Biotech's strength is likely to continue - so it's not too late for investors to get in, sector analysts say.\"Biotech will be a comparative outperformer,\" says Motley Fool biotech analyst Karl Thiel. \"There is better sentiment and fund-flow, and that feeds on itself. That can unravel quickly but I still think it has some legs.\". Stifel's head of biotech research, Paul Matteis, agrees. \"The sector's run has been driven by a number of credible fundamental factors that seem mostly sustainable,\" he said in a recent interview.M&A also puts higher valuations on biotech companies in general because investors start considering how much more profitable potential drugs might be in the hands of companies ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","LU2237443622.USD","LU0545039389.USD","LU1839511570.USD","QURE","LU0786609619.USD","LU1267930490.SGD","LU0471298694.HKD","RAPP","ASND","BBIO","LU1894683264.USD","LU2129689514.USD","LU2237443549.SGD","ABBV","BK4585","LU0965509101.SGD","ALNY","LU1366192091.USD","SG9999014906.USD","ARGX","LU2360106947.USD","SG9999002232.USD","SGXZ81514606.USD","LU2106854487.HKD","MBX","IE00B19Z3B42.SGD","LU0321505439.SGD","LU2237443978.SGD","BMY","SG9999001440.SGD","LU0985481810.HKD","LU0689626769.HKD","LU1093756325.SGD","NBIX","IE00BGHQF631.EUR","LU2237443382.USD","LU2552382058.USD","LU0553294199.USD","LU0097036916.USD","BK4548","PRAX","MDGL","LU2242646821.SGD","ALKS","LU1623119135.USD","LU2168563687.JPY","AMGN"],"gpt_icon":1},{"id":"2581882441","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zymeworks (ZYME), MBX Biosciences, Inc. (MBX) and Lemaitre Vascular (LMAT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581882441","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581882441?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:50","pubTimestamp":1762530624,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zymeworks (ZYME – Research Report), MBX Biosciences, Inc. (MBX – ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-zymeworks-zyme-mbx-biosciences-inc-mbx-and-lemaitre-vascular-lmat-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-zymeworks-zyme-mbx-biosciences-inc-mbx-and-lemaitre-vascular-lmat-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4585","ZYME","BK4137","BK4581","MBX","XBI","XLV","LU0128526141.USD","LU0029874061.USD","BK4588","BK4082","LMAT","BK4007","LABU","BK4139"],"gpt_icon":0},{"id":"2581402141","title":"MBX Biosciences, Inc. (MBX) Receives a Buy from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2581402141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581402141?lang=en_us&edition=fundamental","pubTime":"2025-11-07 11:35","pubTimestamp":1762486525,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Uy Ear reiterated a Buy rating on MBX Biosciences, Inc. yesterday and set a price target of $57.00. According to TipRanks...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mbx-biosciences-inc-mbx-receives-a-buy-from-mizuho-securities-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mbx-biosciences-inc-mbx-receives-a-buy-from-mizuho-securities-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","MFG","MBX","BK4007"],"gpt_icon":0},{"id":"2581524096","title":"BRIEF-Mbx Biosciences To Offer Up To $400 Million In Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581524096","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581524096?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:39","pubTimestamp":1762436368,"startTime":"0","endTime":"0","summary":"BRIEF-Mbx Biosciences To Offer Up To $400 Million In Securities - SEC FilingNov 6  - MBX Biosciences Inc MBX.O:MBX BIOSCIENCES INC - TO OFFER UP TO $400 MILLION IN SECURITIES - SEC FILINGSource text: [ID:n0001193125-25-268202]Further company coverage: MBX.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nFWN3WI298:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2581096138","title":"Mbx Biosciences Inc - to Offer up to $400 Mln in Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581096138","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581096138?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:38","pubTimestamp":1762436291,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nFWN3WI298:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MBX"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":121,"code":"91000000","status":"200"}]}}